Assessment and management of portal hypertension in patients with MASLD: advances and caveats.

Journal: Expert review of gastroenterology & hepatology
Published Date: Jul 12, 2025

Abstract

INTRODUCTION: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly gaining relevance both as a public health issue and a clinical challenge. The development of portal hypertension in MASLD challenges traditional paradigm that it arises only in the context of cirrhosis.

Authors

  • Diego Rojo
    Liver Unit, Division of Digestive Diseases, Vall d'Hebron University Hospital.
  • Alba Jiménez-Masip
    Liver Unit, Division of Digestive Diseases, Vall d'Hebron University Hospital.
  • Laura Pagès
    Liver Unit, Division of Digestive Diseases, Vall d'Hebron University Hospital.
  • Juan Bañares
    Liver Unit, Division of Digestive Diseases, Vall d'Hebron University Hospital.
  • Clara Sabiote
    Vall d'Hebron Institute of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus.
  • María Martínez-Gómez
    Vall d'Hebron Institute of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus.
  • Laia Aceituno
    Liver Unit, Division of Digestive Diseases, Vall d'Hebron University Hospital.
  • M Serra Cusidó
    Vall d'Hebron Institute of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus.
  • M Teresa Salcedo-Allende
    Vall d'Hebron Institute of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus.
  • Zyanya Calixto
    Vall d'Hebron Institute of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus.
  • Mònica Pons
    Liver Unit, Division of Digestive Diseases, Vall d'Hebron University Hospital.
  • Joan Genescà
    Liver Unit, Division of Digestive Diseases, Vall d'Hebron University Hospital.
  • Juan M Pericàs
    Liver Unit, Division of Digestive Diseases, Vall d'Hebron University Hospital.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals